Jam

United Microelectronics Corporation (UMC) exceeded market expectations with strong June 2025 net sales. This robust performance highlights UMC’s resilient operations and strategic position in the dynamic semiconductor market. The foundry giant’s growth, fueled by demand in AI, automotive, and IoT, signals a promising outlook for the second half of 2025.

Dream Vacations launches its 14th annual “Operation Vetrepreneur” contest, offering U.S. military veterans a chance to win a complimentary travel agency franchise. This year’s grand prize includes a franchise, a Carnival cruise for two, and comprehensive training. The contest aims to empower veterans with entrepreneurial opportunities, continuing a legacy of over $787,200 in gifted franchises since 2012. Applications are open until September 1, 2025.

Innate Pharma announced its total outstanding shares and voting rights as of July 3, 2025. The company reported 92,183,523 ordinary shares and 6,434, plus 7,581 preferred shares. Total theoretical voting rights stood at 92,962,943, with 92,944,368 exercisable rights. This disclosure complies with French regulatory requirements.

Honey Badger Silver Inc. successfully closed the first tranche of its private placement, raising approximately $2.01 million. The financing, involving non-flow-through units and flow-through shares, will fund exploration on properties in the Yukon, Northwest Territories, and Nunavut, as well as property advancement and acquisitions. Prominent investor Eric Sprott participated in the round.

QT Imaging Holdings, Inc. announced its 2025 virtual Annual Meeting of Stockholders, scheduled for August 19, 2025. Registered shareholders as of July 16, 2025, are eligible to vote. Details for the webcast are available in the proxy statement and on the company’s website. QT Imaging is an innovator in medical imaging technology, focusing on low-frequency sound waves for disease detection and treatment.

Butler National Corporation reported record earnings of $0.19 per share and a 27% year-over-year surge in operating income to $16.8 million for fiscal year 2025. The company saw strong performance in its Aerospace Products segment, with revenue up 15%, driven by new aircraft modifications and increased deliveries. The Professional Services segment remained stable. Butler National also announced strategic investments in new product development and expansion of fabrication capabilities.

Liberty Energy Inc. (NYSE: LBRT) will release its second-quarter financial results after market close on Wednesday, July 23, 2025. The company will host a conference call to discuss its performance on Thursday, July 24, 2025. Liberty is a leading North American provider of completion services and technologies, also investing in power and storage solutions.

Monte Rosa Therapeutics’ AI platform, QuEEN™, has identified a vast array of human proteins targetable by molecular glue degraders (MGDs). Published in *Science*, this breakthrough significantly expands the universe of “undruggable” therapeutic targets, particularly for MGDs via cereblon. The company is integrating these AI-driven insights to accelerate its pipeline of novel MGD medicines, aiming to transform patient outcomes in oncology, immunology, and inflammation.

CoreWeave, the AI Hyperscaler, announces it is the first AI cloud provider to deploy NVIDIA’s latest GB300 NVL72 systems, promising significant performance boosts for AI reasoning and agentic workloads. This strategic move, supported by partnerships with Dell, Switch, and Vertiv, reinforces CoreWeave’s commitment to offering state-of-the-art AI infrastructure for global innovators.

Hemostemix’s ACP-01 therapy, a novel cellular treatment for heart failure, has been detailed in a peer-reviewed paper. Targeting non-ischemic dilated cardiomyopathy, ACP-01 utilizes autologous cells to combat inflammation, fibrosis, and improve blood flow. Earlier studies showed significant improvement in cardiac function, with LVEF increases up to 47.1% in DCM patients. The therapy is now available in Florida under new legislation, offering a promising option for patients with limited alternatives.